Mohammed Mohiuddin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammed Mohiuddin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Majid M. Mohiuddin
Department of Oncology, University of Texas – Health Science Center at Houston, Houston, Texas, USA
2 shared publicationsAlbert Yuen
Reading Hospital and Medical Center P.O. Box 16052 6th and Spruce Street Reading, PA 19612
1 shared publication- Anand Mahadevan
Department of Radiation Oncology, New York University, Langone Health, New York, NY 10016, USA
1 shared publication - Beatriz E. Amendola
Innovative Cancer Institute, South Miami, FL 33143, USA
1 shared publication - Charles B. Simone
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication Charles R. Thomas
Department of Radiation Medicine, OHSU Knight Cancer Institute, Portland, OR
1 shared publication
Latest Publications
- Open Access
An International Consensus on the Design of Prospective Clinical–Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer
Despite the unexpectedly high tumor responses and limited treatment-related toxicities observed with SFRT, prospective multi-institutional clinical trials of SFRT are still lacking. High variability of SFRT technologies and methods, unfamiliar complex dose and prescription concepts for heterogeneous dose and uncertainty regarding systemic therapies present major obstacles towards clinical trial development. To address these challenges, the consensus guideline reported here aimed at facilitating trial development and feasibility through a priori harmonization of treatment approach and the full range of clinical trial design parameters for SFRT trials in gynecologic cancer. Gynecologic cancers were evaluated for the status of SFRT pilot experience. A multi-disciplinary SFRT expert panel for gynecologic cancer was established to develop the consensus through formal panel review/discussions, appropriateness rank voting and public comment solicitation/review. The trial design parameters included eligibility/exclusions, endpoints, SFRT technology/technique, dose/dosimetric parameters, systemic therapies, patient evaluations, and embedded translational science. Cervical cancer was determined as the most suitable gynecologic tumor for an SFRT trial. Consensus emphasized standardization of SFRT dosimetry/physics parameters, biologic dose modeling, and specimen collection for translational/biological endpoints, which may be uniquely feasible in cervical cancer. Incorporation of brachytherapy into the SFRT regimen requires additional pre-trial pilot investigations. Specific consensus recommendations are presented and discussed.
Open AccessAn International Consensus on the Design of Prospective Clinical–Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer
Despite the unexpectedly high tumor responses and limited treatment-related toxicities observed with SFRT, prospective multi-institutional clinical trials of SFRT are still lacking. High variability of SFRT technologies and methods, unfamiliar complex dose and prescription concepts for heterogeneous dose and uncertainty regarding systemic therapies present major obstacles towards clinical trial development. To address these challenges, the consensus guideline reported here aimed at facilitating trial development and feasibility through a priori harmonization of treatment approach and the full range of clinical trial design parameters for SFRT trials in gynecologic cancer. Gynecologic cancers were evaluated for the status of SFRT pilot experience. A multi-disciplinary SFRT expert panel for gynecologic cancer was established to develop the consensus through formal panel review/discussions, appropriateness rank voting and public comment solicitation/review. The trial design parameters included eligibility/exclusions, endpoints, SFRT technology/technique, dose/dosimetric parameters, systemic therapies, patient evaluations, and embedded translational science. Cervical cancer was determined as the most suitable gynecologic tumor for an SFRT trial. Consensus emphasized standardization of SFRT dosimetry/physics parameters, biologic dose modeling, and specimen collection for translational/biological endpoints, which may be uniquely feasible in cervical cancer. Incorporation of brachytherapy into the SFRT regimen requires additional pre-trial pilot investigations. Specific consensus recommendations are presented and discussed.
- 1 July 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 86 (3) , 523-528
Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer
- 1 July 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 86 (3) , 523-528
Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer
- 1 July 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (3) , 643-644
Will There be a Future Role for Radiation in the Neo-Adjuvant Therapy for Rectal Cancer?
- 1 July 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (3) , 643-644
Will There be a Future Role for Radiation in the Neo-Adjuvant Therapy for Rectal Cancer?
- 1 April 2011
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 22 (4) , 351-361
New directions in neoadjuvant therapy for rectal cancer
Neoadjuvant chemoradiation therapy in rectal cancer has yielded exciting data on response to treatment and is now widely accepted as essential for the optimum treatment of this disease. Although a variety of drugs (5-fluorouracil, irinotecan, oxaliplatin) and molecular targeted therapy (vascular endothelial growth factor inhibitors, epidermal growth factor receptor inhibitors, etc.) are being explored as single agents or in combination with radiotherapy, the results of treatment have plateaued with response rates of 65–70% and complete pathological responses of 10–20%. This review analysis makes it possible for the underlying factors in the continued lack of improvement and examines potential new directions for future approaches to management of this disease.
- 1 April 2011
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 22 (4) , 351-361
New directions in neoadjuvant therapy for rectal cancer
Neoadjuvant chemoradiation therapy in rectal cancer has yielded exciting data on response to treatment and is now widely accepted as essential for the optimum treatment of this disease. Although a variety of drugs (5-fluorouracil, irinotecan, oxaliplatin) and molecular targeted therapy (vascular endothelial growth factor inhibitors, epidermal growth factor receptor inhibitors, etc.) are being explored as single agents or in combination with radiotherapy, the results of treatment have plateaued with response rates of 65–70% and complete pathological responses of 10–20%. This review analysis makes it possible for the underlying factors in the continued lack of improvement and examines potential new directions for future approaches to management of this disease.
- 1 November 2009
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 35 (7) , 547-552
Future directions in neoadjuvant therapy of rectal cancer: Maximizing pathological complete response rates
- 1 November 2009
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 35 (7) , 547-552
Future directions in neoadjuvant therapy of rectal cancer: Maximizing pathological complete response rates